



**ASC X12N TGB WG2 Minutes Claims Encounters and Attachments Information Work Group January 26-30, 2020  
Portland, OR**

<b>Group Leadership</b>			
<b>Chair Name</b>	<b>Company</b>	<b>Term End Date</b>	<b>Email</b>
Jamie Mosteller	Cerner	Summer 2019	<a href="mailto:james.mosteller@cerner.com">james.mosteller@cerner.com</a>
Lynn Chapple	United Health Group	Winter 2021	<a href="mailto:lynn.chapple@optum.com">lynn.chapple@optum.com</a>
Marci Maisano	Cigna	Summer 2020	<a href="mailto:marci.maisana@cigna.com">marci.maisana@cigna.com</a>
Open Position			
<b>Secretary Name</b>	<b>Company</b>	<b>Term End Date</b>	<b>Email</b>
Tracy Loetz	REMEDI Electronic Commerce Group	Summer 2021	<a href="mailto:tloetz@remedi.com">tloetz@remedi.com</a>

<b>Quorum Requirement Statement</b>	
<i>This group enforces quorum requirements for group voting items.</i>	
<i>This group does not enforce quorum requirements for group voting items.</i>	X

<b>Scheduled Meetings</b>				
<b>Type of Meeting</b>	<b>Date</b>	<b>Location/Conference Call</b>	<b>Contact</b>	<b>Agenda</b>
<b>Current Meeting</b>	Jan 26-30, 2020	Hilton Portland Downtown 921 SW Sixth Avenue Portland, OR 97204 (503) 220-2565	Co-chairs	See iMeet for meeting information
<b>Next Standing Meeting</b>	May 31-Jun 4, 2020	Hyatt Regency Jacksonville Riverfront 225 E Coastline Dr. Jacksonville, FL 32202 (904) 588-1234	Co-chairs	See iMeet for meeting information
<b>Interim Meeting</b>	2 <sup>nd</sup> and 4 <sup>th</sup> Thursdays 1:00-2:30 pm Eastern	(605) 468-8018 Access Code: 219956	Co-chairs	See iMeet for meeting information
<b>Management Meeting</b>				



<b>Co-chair Election</b>	<b>Term End</b>	<b>Election Date: 1/28/2020</b>			
	<b>Candidate(s)</b>				
<b>Nomination</b>	Stanley Nachimson				
	<b>Motion</b>				
	Motion to nominate Stanley Nachimson as TGB/WG2 co-chair through Summer 2021				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Stanley Nachimson	Mary Lynn Bushman		0	0
<b>Election</b>					
	Motion to elect Stanley Nachimson as TGB/WG2 co-chair through Summer 2021 by unanimous consent				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Mary Lynn Bushman	Jeffrey Jennings		0	0

<b>Voting Item:</b>			<b>Vote Date: 1/27/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Supportive UDI comments from 837 second public review period				
	<b>Motion</b>				
	Accept all supportive UDI comments by the work group for the 837				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Mike Denison		0	0
<b>Discussion</b>	None				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/27/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65256 and 65330 – 1.12.7 UDI from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept verbiage change in Section 1.12.7				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Lynn Chapple	Mary Lynn Bushman	18	5	12
<b>Discussion</b>	<ul style="list-style-type: none"> <li>• Discussion on appropriate verbiage - high risk implantable medical devices or "high-risk implant"</li> <li>• list of high risk is not available anywhere and previous TR3 notes indicate that the NUBC/NUCC would provide a list, but that has not happened and likely will not happen with much debate over what is high-risk</li> <li>• FDA representative says they have defined by classes - low, moderate, high</li> <li>• Reminder that we just provide data, not determine why or why not regulations exist</li> <li>• CMS does not require providers to send that information on claims so they cannot pass that on to FDA for surveillance</li> </ul>				
<b>Result</b>	Motion passed				

<b>Voting Item:</b>			<b>Vote Date: 1/27/2020</b>		
<b>Type</b>	<b>Issue Description</b>				



Other	Comment 65392 – 1.12.7 UDI from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept verbiage change in Section 1.12.7				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Stanley Nachimson	10	5	14
<b>Discussion</b>	<ul style="list-style-type: none"> <li>Same discussion as above</li> <li>Nancy Spector from the AMA disagrees on the use of the claim for this information. It is a burden on the industry to send data to be used for surveillance purposes when it has not been used for this purpose as well as not knowing if it will be useful.</li> </ul>				
<b>Result</b>	Motion passed				

<b>Voting Item:</b>		<b>Vote Date: 1/28/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65325 – Oppose UDI Collection on Claims Form, 65333 – Clarifying definition of high-risk implantable device, and 65401 – AdvaMed Comments on UDI from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept responses to all three comments				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Stanley Nachimson	Steve Cloutier	17	6	14
<b>Discussion</b>	<ul style="list-style-type: none"> <li>Clarification – Are we voting on definition of high-risk? No, we are voting on the removal of the reference to a high-risk list being available from NUBC/NUCC.</li> <li>Is there anything in the code that prevents NUBC/NUCC from coming up with a list of high-risk in the future? NUBC/NUCC had experts try to hash this out for two years and were unable to, so the likelihood is not good they will develop a list.</li> </ul>				
<b>Result</b>	Motion passed				

<b>Voting Item:</b>		<b>Vote Date: 1/28/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65225, 65229, 65278, 65405, 65404, 65048, 65409, 65051, 65338, 65190, 65193, 65195, 65197, 65198, 65199, 65208, 65210, 65220, 65221, 65215 from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept responses to all comments listed above				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Sarah Vandermolen		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	<ul style="list-style-type: none"> <li>Comments relating to 65125 from 275 Informational Forum on Tuesday, January 27, 2020 at 2:30 pm (Details can be found at: <a href="#">09 - B2 - All initial posts (275) working document .xlsx</a>)</li> </ul>				
	<b>Motion</b>				
	Motion to accept change request for CAT02 with IA qualifier to remove reference to CDA				



<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Mary Lynn Bushman	Matt Klischer		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>Copy of existing comment number 65125 was added and named 65125.1</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Comment 65125.1 – CAT02 HL Qualifier Note (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept solution to comment 65125.1				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Move 275 X341 7030 to publication pending approval from TGA/WG4				
	<b>Motion</b>				
	Motion to accept to move 275 to publication				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65227, 65262, 65263, 65324, 65393, 65400 from 837 second public review period				
	<b>Motion</b>				
	Motion to accept responses to all comments listed above				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Mary Lynn Bushman	Stanley Nachimson		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1526</a> – 7030 275 (X341) Unsolicited Claim Attachment Example				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				



<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1603</a> – Capture frame and/or lens information that was dispensed during office visit by provider, <a href="#">CR1604</a> – Capture manufacturing information for contacts				
	<b>Motion</b>				
	Motion to close BRTSs above due to lack of feedback from submitter				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mike Denison		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1645</a> – Consistency needed for terminology, i.e. hyphen vs. no hyphen in “post adjudicated”				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1662</a> – Ability to capture vision prescription (eyeglass or contact lens) information in 837				
	<b>Motion</b>				
	Motion to close BRTS above due to lack of feedback from submitter				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1675</a> – Modify data element usage in LIN to capture additional NDC codes for compound drugs				
	<b>Motion</b>				
	Motion to close BRTS – submitter is OK with current functionality				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>		<b>Vote Date: 1/29/2020</b>			
<b>Type</b>	<b>Issue Description</b>				



Other	<a href="#">CR1728</a> – Modifications to 2310D and 2310A Supervising and Referring loops				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Sarah Vandermolen		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1777</a> – Change Usage Note in 837D DN104				
	<b>Motion</b>				
	Motion to close BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mike Denison		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1835</a> – Add timestamp at the detail/service level on the 837 Professional and Institutional claim transaction				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1850</a> – Appropriate Use Criteria (AUC) Mandate				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1957</a> – Add TOO segment to Loop 2400 837I				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>



	Jamie Mostettler	Matt Klischer		0	0
<b>Discussion</b>	• None				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/29/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	<a href="#">CR1952</a> – Additional prior authorization numbers (REF) on the 837I				
	<b>Motion</b>				
	Motion to approve BRTS				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Jamie Mostettler	Mary Lynn Bushman		0	0
<b>Discussion</b>	• None				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/30/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65191 – LIN – Drug/Supply Identification from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept response				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Stanley Nachimson	Laurie Burckhardt		0	0
<b>Discussion</b>	• None				
<b>Result</b>	Motion passed unanimously				

<b>Voting Item:</b>			<b>Vote Date: 1/30/2020</b>		
<b>Type</b>	<b>Issue Description</b>				
Other	Comments 65222, 65231, 65234, 65251, 65252, 65253, 65254, 65255, 65232, 65257, 65261, 65273, 65279, 65313, 65211, 65315, 65316, 65336, 65280, 65321, 65322, 65343, 65016, 65223 from 837 second public review period (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a> )				
	<b>Motion</b>				
	Motion to accept responses to all comments listed above				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Mary Lynn Bushman		0	0
<b>Discussion</b>	• None				
<b>Result</b>	Motion passed unanimously				



<b>Voting Item:</b>		<b>Vote Date: 1/30/2020</b>			
<b>Type</b>	<b>Issue Description</b>				
Other	Schedule informational meeting for 837s				
	<b>Motion</b>				
	Motion to hold an interim Informational Forum for the 837s				
<b>Vote</b>	<b>Motion Made by</b>	<b>2<sup>nd</sup> By</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
	Laurie Burckhardt	Mary Lynn Bushman		0	0
<b>Discussion</b>	<ul style="list-style-type: none"> <li>None</li> </ul>				
<b>Result</b>	Motion passed unanimously				

<b>Key Discussion Items</b>	
<b>Monday 1/27/2020</b>	
<b>Discussion – X341 Claim Attachment (275) Informational Forum</b>	
<ul style="list-style-type: none"> <li>Informational Forum will be held Tuesday, January 28 at 2:30 pm in Pavilion West</li> <li>Mary Lynn Bushman gave update on attachments with HL7 and her company <ul style="list-style-type: none"> <li>HL7 update - FHIR, DaVinci - going through comments, CMS wants more pilots with FHIR before regulations</li> <li>Mary Lynn talked about their implementation of attachments - providers getting paid faster – her company implemented appeals using 275 with very good results</li> <li>About 9% of attachments are coming through EDI</li> <li>Payers do not have technical support for HL7 attachments</li> <li>HIPAA regulation changes may not be on the same schedule as the X12 annual guide changes</li> </ul> </li> </ul>	
<b>Decisions</b>	
<ul style="list-style-type: none"> <li>None</li> </ul>	
<b>Discussion – Review of impact statements for 275</b>	
<ul style="list-style-type: none"> <li>Details can be found at: <a href="#">BAR WG2 7030 275.xlsx</a></li> <li>Added the following (last 3 rows of spreadsheet): <ul style="list-style-type: none"> <li>Addition of the DTM segment</li> <li>Updated REF segment to support MBI</li> <li>Removing recommendation to limit the transaction size to not be greater than 64mb</li> </ul> </li> <li>Removed items that were left over from 5010 to 6020</li> </ul>	
<b>Decisions</b>	
<ul style="list-style-type: none"> <li>None</li> </ul>	
<b>Discussion – Review of impact statements for 837</b>	
<ul style="list-style-type: none"> <li>Details can be found at: <a href="#">BAR WG2 7030 837.xlsx</a></li> </ul>	
<b>Decisions</b>	
<ul style="list-style-type: none"> <li>None</li> </ul>	





<b>Tuesday 1/28/2020</b>
<b>Discussion – Q&amp;A regarding ARC process</b>
<ul style="list-style-type: none"><li>• Two comments from ARC process review<ul style="list-style-type: none"><li>○ Appears to be the elimination of the public comment period</li><li>○ Seems to be more accessible to a non-X12er</li></ul></li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• None</li></ul>
<b>Discussion – Comment 65333 - Clarifying definition of high-risk implantable device</b>
<ul style="list-style-type: none"><li>• Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a></li><li>• Nancy Spector from AMA made a motion to have a third public comment review due to changes to front matter Section 1.12.7 regarding the definition of high-risk medical devices indicating the changes are substantive. Her points were:<ul style="list-style-type: none"><li>○ No definition of high-risk as indicated there would be according to the note</li><li>○ Changes to Section 1.12.7 now does not match front matter</li><li>○ Does not match CR8 segment</li><li>○ These changes will require significant amount of changes for companies</li></ul></li><li>• Laurie Burckhardt denied motion because there are not technical changes and therefore not substantive.</li><li>• Definition of substantive approved by TGA/WG4 in October 2018: Any modification that would cause a change in the use of a technical report or change the requirements for compliance to that technical report.</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• None</li></ul>
<b>Discussion – Comment 65190 – 1.4.2.1 – RARCs are not available to post in MIA or MOA for the 7030 837I</b>
<ul style="list-style-type: none"><li>• Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a></li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• Pass to TGB/WG3</li></ul>
<b>Discussion – Review of topics discussed during management meeting</b>
<ul style="list-style-type: none"><li>• The new process will start with WG22 and the Data Reporting 837 (837R)</li><li>• WG4 folding into WG16</li><li>• Need a 7030 example for each guide by summer standing meeting – appears that only 5010 examples are currently available on website so it will take a little more work than it would starting from a 6020 guide</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• <b>We will need volunteers to create examples for each guide</b></li></ul>
<b>Wednesday 1/29/2020</b>
<b>Discussion – Comment 65223 – 2400 DTP01 – Service Date</b>
<ul style="list-style-type: none"><li>• Accommodating this in the first place added complexity that was already taken care of in the industry</li><li>• Names of elements should be enough to explain to use one qualifier over another</li><li>• Still problem with wording if drug administered on same day</li><li>• Discussion around whether we should have such detailed notes or remove and go back to verbiage in 5010</li><li>• Will it cause a problem for industry if we change so that D8 is one date and RD8 is a range - what if providers use RD8 and the dates are the same?</li><li>• Many providers are sending same dates in RD8, so this could cause claims to stop at door if we do not say it is OK to do so</li></ul>



<ul style="list-style-type: none"><li>• CR1503 needs to be pulled and looked at to determine original reasoning</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• None</li></ul>
<b>Discussion – Review of X12N Full Committee meeting</b>
<ul style="list-style-type: none"><li>• Laurie Burckhardt explained the topic regarding publishing 7030 and overlaying it with 8010 standards<ul style="list-style-type: none"><li>○ any changes to 8010 will be flagged as Not Used</li><li>○ Staff reviewing what changes are between 7030 to 8010 to determine impact</li><li>○ Assumption is that staff will compare 7030 to 8010</li><li>○ What happens with K3? - prior rule is that K3s are found a permanent place in next version - Jamie and Lynn will move that question to management</li></ul></li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• Follow up with management regarding how K3s are handled</li></ul>
<b>Discussion - <a href="#">CR1526</a> – 7030 275 (X341) Unsolicited Claim Attachment Example</b>
<ul style="list-style-type: none"><li>• Modifications to BRTS example<ul style="list-style-type: none"><li>○ Change CAT02 to HL</li><li>○ Change code note verbiage from HL <i>Standard</i> to HL <i>Document</i> in BDS</li><li>○ Updated sample dates</li></ul></li></ul>
<b>Discussion – <a href="#">CR1697</a> – Orthodontic “Initial Claims” Not Supported in the X12 837D Format</b>
<ul style="list-style-type: none"><li>• BRTS updated by Mike Denison</li><li>• Still discussing in Dental Caucus</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• None</li></ul>
<b>Discussion – <a href="#">CR1890</a></b>
<ul style="list-style-type: none"><li>• CMS still working on</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• None</li></ul>
<b>Thursday 1/30/2020</b>
<b>Discussion – Comment 65016 – SV421 – Compound Route of Administration Code</b>
<ul style="list-style-type: none"><li>• Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a></li><li>• Previously discussed on 1/23/2020 interim call, revisited since commenter was in attendance</li><li>• Commenter explained that the code note did not indicate a complete compound - they need the individual items, but the price is on the complete compound form (ml, ea, gram)</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• Motion to approve comment response passed; refer to Voting Item</li></ul>
<b>Discussion – Comment 65223 – 2400 DTP01 – Service Date</b>
<ul style="list-style-type: none"><li>• Revisited from discussion on 1/29/2020</li><li>• Why was this changed from 5010?</li><li>• Reviewed 837P and the DTP code note for RD8 contradicts the element note</li><li>• Confusion as to why drug billed has to do with it - it could be anything - drug, assessment, etc.</li><li>• Someone needs to be tasked to bring up at informational forum data element note and D8 code note contradict each other on the 837P</li></ul>
<b>Decisions</b>
<ul style="list-style-type: none"><li>• Motion to approve comment response passed; refer to Voting Item</li><li>• Must be brought up at Informational Forum for 837s – data element note and D8 code note contradict each other (Details can be found at: <a href="#">09 - B2 - All initial posts (837s) PR2 Master.xlsx</a>)</li></ul>
<b>Discussion – Change Requests</b>



- Prioritized change requests
- There are 34 change requests that need to be entered
- Need to check with Kelly Butler to see how she would prefer them grouped

**Decisions**

- Check with Kelly Butler on how CRs should be grouped and determine how to divide among members at the next interim meeting

**Informational Forum or Joint Meeting Notes:**

**Topic**

**Date:** Click or tap to enter a date.

**Notes**